Why the study?
Does pimagedine prevent the progression of overt nephropathy in patients with type 1 diabetes?
Does pimagedine prevent the progression of overt nephropathy in patients with type 1 diabetes?
Although it did not reach statistical significance for its primary endpoint, the study provides the first clinical proof of concept that inhibiting advanced glycation end product formation can attenuate serious complications of type 1 diabetes.
No takes yet. Share an insight, caveat, or question.
Pimagedine does not significantly slow overt nephropathy progression in type 1 diabetes; leaves open whether AGE inhibition confers clinical benefit.
Bolton et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: